OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Jagannath on the Safety of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

May 14th 2024

Sundar Jagannath, MBBS, discusses the safety of linvoseltamab in relapsed/refractory multiple myeloma.

Dr Leslie on the Management of CAR T-Cell Therapy Toxicities in LBCL

May 14th 2024

Lori A. Leslie, MD, discusses the evolution in managing toxicities associated with CAR T-cell therapy in patients with LBCL.

Dr Ignatz-Hoover on Sequencing CAR T-Cell Therapy and Bispecific Antibodies in R/R Myeloma

May 14th 2024

James Ignatz-Hoover, MD, PhD discusses sequencing CAR T cell therapies and bispecific agents in treating pretreated patients with multiple myeloma.

Dr Liu on the Rationale for Targeting Wee1 in Ovarian Cancer

May 13th 2024

Joyce F. Liu, MD, MPH, discusses the role of Wee1 in cell cycle regulation and the rationale for targeting this protein in ovarian cancer.

Dr Pederson on Novel Therapies for the Management of Targetable mCRC

May 13th 2024

Katrina S. Pedersen, MD, MS, discusses key updates in the therapeutic landscape for patients with molecularly targetable metastatic colorectal cancer.

Dr Tripathy on Real-World HER2 Testing and CDK4/6 Inhibitor Use in HER2+ Breast Cancer

May 13th 2024

Debu Tripathy, MD, discusses real-world strategies for CDK4/6 inhibitor use and the importance of HER2 testing in HER2-positive metastatic breast cancer.

Dr Deng on the Evolution of the Hodgkin Lymphoma Treatment Paradigm

May 13th 2024

Changchun Deng, MD, PhD, discusses the evolution of Hodgkin lymphoma management following data readouts at the 2023 ASH Annual Meeting.

Dr Bellmunt on Enfortumab Vedotin/Pembrolizumab in the Community Setting for Urothelial Carcinoma

May 13th 2024

Joaquim Bellmunt, MD, PhD, discusses treatment with enfortumab vedotin plus pembrolizumab in patients with urothelial carcinoma in the community setting.

Dr Qian on Preclinical Data for a CXCR4 Partial Agonist Plus Anti–PD-1 Therapy in Gastric Cancer.

May 13th 2024

Jin Qian, PhD, discusses preclinical findings for CXCR4 partial agonist in combination with anti–PD-1 therapy in advanced gastric cancer.

Dr Yap on Saruparib in BRCA1/2+, PALB2+, or RAD51C/D+ Advanced Solid Tumors

May 13th 2024

Timothy Yap, MBBS, PhD, FRCP, discusses data for saruparib in harboring BRCA1/2, PALB2, or RAD51C/D mutations.

Dr Barry on the Rationale for Using Partial Breast Irradiation in Breast Cancer Management

May 10th 2024

Ramez Kouzy, MD, discusses efforts to improve knowledge of the use of AI in radiation oncology through the creation of an online repository.

Dr Kouzy on the Creation of a Centralized Resource to Inform AI Use in Radiation Oncology

May 10th 2024

Ramez Kouzy, MD, discusses efforts to improve knowledge of the use of AI in radiation oncology through the creation of an online repository.

Dr Fox on a Dark Matter–Containing Multivalent Vaccine in Head and Neck Cancer

May 10th 2024

Bernard A. Fox, PhD, discusses an off-the-shelf multivalent vaccine that contains cancer’s dark matter combined with anti–PD-1 and anti-GITR antibodies in head and neck cancer.

Dr Corr on the Rationale for Investigating Rucaparib Maintenance in Endometrial Cancer

May 10th 2024

Bradley R. Corr, MD, discusses a phase 2 study evaluating rucaparib maintenance therapy in patients with metastatic and recurrent endometrial cancer.

Dr Muzaffar on the Evaluation of FLX475 Plus Pembrolizumab in HNSCC

May 10th 2024

Jameel Muzaffar, MD, discusses a study of FLX475 plus pembrolizumab in patients with head and neck squamous cell carcinoma.

Dr Walker-Mimms on Outcomes With Filanesib in Ewing and Clear Cell Sarcoma

May 10th 2024

Hannah Walker-Mimms, MS, discusses a study revealing that Ewing and clear cell sarcomas have increased sensitivity to filanesib over other cancer types.

Dr Chon on Durvalumab Plus Chemotherapy and Olaparib in Endometrial Cancer

May 10th 2024

Hye Sook Chon, MD, discusses the DUO-E trial of frontline durvalumab plus chemotherapy followed by durvalumab and olaparib in endometrial cancer.

Dr Asare on an AI Model to Predict PFS Outcomes in Ovarian Cancer

May 10th 2024

Amma Asare, MD, PhD on the use of AI for predicting PFS in ovarian cancer

Dr Jagannath on the Safety Considerations With CAR T-Cell Therapy Multiple Myeloma

May 10th 2024

Sundar Jagannath, MBBS, discusses CAR T-cell therapy considerations prior to initiation in the management of multiple myeloma.

Dr Ignatz-Hoover on Bispecific Antibodies in the Multiple Myeloma Treatment Armamentarium

May 9th 2024

James Ignatz-Hoover, MD, PhD, discusses the current arsenal of FDA-approved bispecific antibodies in multiple myeloma.